Share This Author
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
Clinical Pharmacokinetics of Fluoxetine
There appears to be a therapeutic window for fluoxetine, and the pharmacokinetics of this drug are not affected by either obesity or renal impairment, which makes this drug particularly suitable for use in elderly patients with depression.
Clinical pharmacology of atypical antipsychotics: an update
Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine, and these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second- Generation antipsychotic drugs such as olanzapine or clozapine.
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Cytokine Polymorphisms in the Pathophysiology of Mood Disorders
The data support the existence of a genetic profile related to pro-inflammatory cytokines in patients affected by mood disorders and suggest the presence of different pathogenetic mechanisms involved in the susceptibility of phenotypically different mood disorders.
Burnout among psychiatrists in Milan: a multicenter survey.
Data suggested that psychiatrists had higher levels of burnout than other physicians employed in general medical settings and confirmed that job satisfaction could have a protective role.
Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study
Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression.
Augmentative low-frequency rTMS of the right DLPFC combined with brain navigation was effective and well tolerated in a small sample of drug-resistant bipolar depressive patients, even though the lack of a sham controlled group limits confidence in the results.
Understanding the pharmacokinetics of anxiolytic drugs
- A. Altamura, D. Moliterno, S. Paletta, M. Maffini, M. Mauri, S. Bareggi
- Psychology, BiologyExpert opinion on drug metabolism & toxicology
- 14 March 2013
A need for a more balanced assessment of the benefits and risks associated with benzodiazepine use, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment.